Sagespring Wealth Partners LLC Has $5.15 Million Position in Amgen Inc. $AMGN

Sagespring Wealth Partners LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 11.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,725 shares of the medical research company’s stock after buying an additional 1,671 shares during the period. Sagespring Wealth Partners LLC’s holdings in Amgen were worth $5,147,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Sequoia Financial Advisors LLC grew its stake in Amgen by 2.3% in the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after purchasing an additional 3,619 shares in the last quarter. Davis Capital Management acquired a new stake in shares of Amgen in the 3rd quarter valued at approximately $1,841,000. D.A. Davidson & CO. boosted its holdings in shares of Amgen by 2.6% in the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after buying an additional 6,222 shares during the last quarter. Global Wealth Management Investment Advisory Inc. grew its stake in shares of Amgen by 56.2% in the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after buying an additional 4,699 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its stake in shares of Amgen by 18.2% in the third quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock valued at $10,888,000 after buying an additional 6,115 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $347.80 on Friday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a market capitalization of $187.49 billion, a price-to-earnings ratio of 24.44, a PEG ratio of 3.47 and a beta of 0.45. The company has a 50-day simple moving average of $360.29 and a 200 day simple moving average of $327.52. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the prior year, the firm earned $5.31 EPS. The business’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several analyst reports. Erste Group Bank raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. Truist Financial lifted their price objective on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research report on Thursday, January 8th. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. Finally, The Goldman Sachs Group raised their target price on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus target price of $354.60.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.